Drug Profile
Research programme: cellular immunotherapeutics - Commence Bio
Alternative Names: CMB-100; CMB-200; MSC1-Commence Bio; MSC2-Commence Bio; STaRT™Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Commence Bio
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Autoimmune disorders; Ovarian cancer
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Autoimmune disorders in USA (IV)
- 04 Sep 2023 Discontinued - Preclinical for Ovarian cancer in USA (IV)
- 28 Dec 2019 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (IV)